All In Biotech

NDA 206352 · Bristol Myers Squibb

Reyataz

Atazanavir Sulfate · Oral

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jun 2, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

216

68 Phase 3, 2 recruiting

FAERS reports

11,467

10,029 serious, 780 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2024.

REYATAZ ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. Limitations of Use: • REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations (8.4) ] . • Use of REYATAZ with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology (12.4) ] . REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. (1)

Mechanism: Atazanavir is an HIV-1 antiretroviral drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 23, 2017 Supplement 5 · Efficacy LetterLabel
  • Sep 24, 2015 Supplement 3 · Efficacy · priority review LabelLetter
  • Jun 2, 2014 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
  • REYATAZ · ATAZANAVIR SULFATE EQ 50MG BASE/PACKET · POWDER, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atazanavir" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction931
  • anxiety759
  • pain740
  • foetal exposure during pregnancy718
  • emotional distress651
  • depression620
  • anhedonia592
  • renal failure453
  • nephrolithiasis441
  • nausea424
  • fatigue395
  • chronic kidney disease394

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004345
2005459
2006496
2007362
2008395
2009598
2010689
2011769
2012892
2013623
2014720
2015808
2016715
2017553
2018545
2019608
2020605
2021499
2022387
2023207
202488
202566
202636

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reyataz (Atazanavir Sulfate)

2024 spending

$650K

Beneficiaries

57

395 claims

Per beneficiary

$11,409

$38.38 per unit

View as table
YearSpending
2020$2,299,539
2021$1,686,574
2022$1,337,506
2023$958,844
2024$650,335

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 351 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.